Dapagliflozin: a new possibility for managing type 2 diabetes

Dapagliflozin is a new sodium‐glucose transporter protein inhibitor under development for the treatment of type 2 diabetes mellitus. In this Drug profile, Professor Stephen Bain outlines why new treatments are needed, and considers the drug's efficacy and tolerability in clinical trials, to date, as well as its potential place in management. Copyright © 2011 John Wiley & Sons, Ltd.